Pancreatic Cancer Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type {Diagnostic Imaging Tests (CT scan, MRI, Ultrasound, Others), Biopsy, Blood Tests, Liver Function Tests, Others}, By Cancer Type (Exocrine, Adenocarcinoma, Squamous Cell Carcinoma, Colloid Carcinoma, Others), By End User (Hospitals & Clinics, Diagnostic Centers, Others), By Region and Competition, 2020-2030F

Market Overview

Global Pancreatic Cancer Diagnostics Market was valued at USD 2.87 billion in 2024 and is expected to reach USD 4.32 billion by 2030 with a CAGR of 7.05% during the forecast period. This is ascribed to increasing incidence of pancreatic cancer, rising demand for minimally invasive diagnostic procedures, and growing investment in research and development. Pancreatic cancer is a deadly disease that affects the pancreas, a vital organ located in the abdomen that plays a critical role in digestion and metabolism. Unfortunately, pancreatic cancer is notoriously difficult to detect in its early stages, and by the time it is diagnosed, it has often spread to other parts of the body. This is why early detection is critical to improving survival rates, and the demand for pancreatic cancer diagnostics has increased significantly in recent years. One of the main factors that has increased the demand for pancreatic cancer diagnostics is the rising incidence of the disease.  The increasing incidence of pancreatic cancer has led to a growing demand for diagnostic tests that can detect the disease in its early stages.

Another factor that has contributed to the demand for pancreatic cancer diagnostics is the aging population. The majority of instances of pancreatic cancer occur in those over 60, making it more common among older adults. The need for early-pancreatic cancer detection diagnostic tools is projected to grow as the world's population ages.

Key Market Drivers

Rising Incidence of Pancreatic Cancer

The increasing prevalence of pancreatic cancer is a significant driver of the global pancreatic cancer diagnostics market. According to the American Cancer Society, in 2024, approximately 66,440 individuals in the U.S. are projected to be diagnosed with pancreatic cancer, with an estimated 51,750 deaths. This high mortality rate underscores the urgent need for early detection and effective diagnostic tools.​

Globally, the burden of pancreatic cancer is escalating due to factors such as aging populations, lifestyle changes, and environmental influences. The disease's typically late diagnosis and rapid progression contribute to its status as one of the most lethal cancers. Consequently, there is a growing emphasis on developing and adopting advanced diagnostic methods that can detect the disease at an earlier, more treatable stage.​

Government initiatives and funding are also playing a crucial role in driving the market. For instance, the Pancreatic Cancer Action Network (PanCAN) awarded USD 10.5 million for 16 new grants in August 2022 to support research and development activities for early detection and better treatment options. Such investments highlight the global commitment to combatting this aggressive disease through improved diagnostics.​

Advancements in Diagnostic Technologies

Technological innovations are transforming pancreatic cancer diagnostics, offering more accurate, less invasive, and faster detection methods. Advancements such as enhanced imaging, next-generation sequencing, liquid biopsies, and advanced biomarker assays enable earlier and more precise detection. These technologies improve diagnostic precision and facilitate personalized treatment by providing detailed molecular and genetic insights.​

Liquid biopsies, for example, offer a minimally invasive method for early pancreatic cancer detection by analyzing circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs). This allows real-time monitoring of tumor dynamics and characterization of heterogeneity, informing personalized therapies. The integration of artificial intelligence and machine learning in diagnostic imaging has also enhanced the precision of detecting pancreatic anomalies, thereby boosting market growth. ​

Government support and regulatory recognition further bolster these advancements. In January 2023, the U.S. FDA granted breakthrough device designation to the OverC Multi-Cancer Detection Blood Test (MCDBT) for the early diagnosis of various forms of cancers, including pancreatic cancer. Such endorsements accelerate the adoption of innovative diagnostic tools, driving market expansion.​

Download Free Sample Report

Key Market Challenges

Late Diagnosis Due to Non-Specific Symptoms

One of the primary challenges in pancreatic cancer diagnostics is the late diagnosis due to non-specific symptoms. Pancreatic cancer often goes undetected until advanced stages because early symptoms are vague and non-specific, such as abdominal pain, weight loss, and jaundice. This leads to delayed diagnosis and limited treatment options, contributing to high mortality rates. ​

The lack of specific symptoms necessitates the development of more effective screening and diagnostic tools that can detect the disease at an earlier stage. Innovations such as the PAC-MANN blood test, which demonstrated 85% accuracy in early-stage detection when combined with a CA 19-9 blood test, offer promising solutions. However, widespread implementation of such tests requires further validation and regulatory approval.

High Cost and Accessibility of Advanced Diagnostics

The high cost and limited accessibility of advanced diagnostic tools pose significant challenges in the global pancreatic cancer diagnostics market. Advanced diagnostics, such as next-generation sequencing and liquid biopsies, often involve substantial costs, making them less accessible in low- and middle-income countries. This financial barrier limits the widespread adoption of cutting-edge diagnostic technologies.​ Moreover, the infrastructure required to support these advanced diagnostics, including specialized equipment and trained personnel.

Key Market Trends

Emphasis on Early Detection and Personalized Medicine

There is a growing trend towards early detection and personalized medicine in pancreatic cancer diagnostics. Early-stage detection significantly improves treatment outcomes and survival rates. For instance, researchers have developed an experimental blood test that detected 97% of stage 1 and 2 pancreatic cancers in a clinical trial. Such advancements underscore the importance of early diagnosis in managing this aggressive disease.​

Personalized medicine, which tailors’ treatment based on individual genetic profiles, is gaining traction. Genomic testing has proven essential for personalized treatment approaches in pancreatic cancer, identifying actionable mutations that lead to better patient outcomes. Studies showed 100% of patients had detectable alterations, and nearly one-third of advanced patients had their treatment plans modified based on genomic findings. This shift towards personalized diagnostics and treatments is reshaping the pancreatic cancer diagnostics landscape.

Integration of Artificial Intelligence in Diagnostics

The integration of artificial intelligence (AI) and machine learning in pancreatic cancer diagnostics is a notable trend. AI-powered algorithms are being developed to identify early-stage pancreatic tumors through advanced imaging analysis, reducing the risk of misdiagnosis and supporting timely intervention. ​

For example, a research team from Taiwan has been studying a computer-aided detection (CAD) tool that uses AI to detect pancreatic cancer. Such tools enhance the accuracy and efficiency of pancreatic cancer diagnosis, facilitating early detection and treatment. ​

Moreover, AI applications in endoscopic ultrasound and novel biomarkers tests to detect pancreatic lesions early have shown impressive results compared to traditional methods. These advancements are expected to boost the adoption of diagnostic tests at the early stages of the disease.

Segmental Insights

Test Type Insights

Based on Test Type, the diagnostic imaging test segment has emerged as the most widely utilized method in the global pancreatic cancer diagnostics landscape. This dominance is largely due to the crucial role these tests play in the early detection and staging of pancreatic cancer, which is vital for improving patient prognosis and guiding appropriate treatment strategies. Healthcare professionals rely on a range of imaging techniques, including computed tomography (CT) scans, magnetic resonance imaging (MRI), endoscopic ultrasound (EUS), and positron emission tomography (PET) scans, to accurately identify tumors and assess the extent of disease progression. These imaging modalities are often favored for their non-invasive nature and high accuracy in detecting malignancies. Continuous technological advances are further enhancing their utility. Innovations such as 3D imaging, improved contrast agents, and the integration of artificial intelligence (AI) into imaging platforms are increasing diagnostic precision and efficiency. Efforts by research institutions to develop more advanced imaging solutions also support the segment’s continued growth. For example, a team in Taiwan is actively researching a computer-aided detection tool that leverages AI to identify pancreatic cancer with higher accuracy.

Download Free Sample Report

Regional Insights

Based on the region, North America held the largest share of the global pancreatic cancer diagnostics market. This dominance can be attributed to a combination of factors including the region’s well-established healthcare infrastructure, high awareness about early cancer diagnosis, and greater access to advanced diagnostic technologies. The United States and Canada are home to some of the leading research institutions, hospitals, and biotechnology firms that continue to invest heavily in the development of innovative diagnostic tools. Additionally, favorable reimbursement policies, strong presence of market players, and ongoing government initiatives aimed at cancer research and early detection contribute to the region’s leading position. The high incidence of pancreatic cancer in the region also drives consistent demand for accurate and early diagnostic methods. Moreover, North America has a mature regulatory environment that facilitates quicker adoption of novel diagnostic solutions, further reinforcing its position as a key market for pancreatic cancer diagnostics globally.

Recent Developments

• In February 2025, ClearNote Health announced that the Clinical Laboratory Evaluation Program (CLEP) by the New York State Department of Health approved its Avantect Pancreatic Cancer Test. The test is a high-sensitive blood test to detect the biological signals of pancreatic cancer in its earliest stages for patients with known risk factors.
• In December 2024, the U.S. FDA granted accelerated approval of a new targeted therapy for NRG1 gene fusion in patients with pancreatic adenocarcinoma. Bizengri, targeted therapy, is approved for the treatment of pancreatic cancer and metastatic non-small cell lung cancer.
• In November 2024, Lokon Pharma announced a clinical collaboration with BeiGene to combine LOAd703, a tumor microenvironment (TME) gene engineering product, with BeiGene’s anti-PD-1 antibody tislelizumab in patients with pancreatic cancer. The combination was made for their upcoming randomized phase 2 clinical trial with patients with stage 4 pancreatic cancer.
• In February 2024, FUJIFILM India, a pioneer in diagnostic imaging and information systems, has launched the groundbreaking ALOKA ARIETTA 850 Diagnostic Ultrasound System in India with its first-ever installation at Fortis Hospital in Bengaluru, Karnataka, the state leading healthcare services provider. Representing a remarkable advancement in endoscopic technologies, the high-tech ultrasound system aims to enhance diagnostic precision and image clarity for gastrointestinal diseases in the region.
• In October 2024, Toray Industries, Inc., announced that it concluded a collaborative agreement (with the University of Tsukuba. They have since launched the Special Joint Research Project on Healthy Longevity and Patient Quality of Life at a new university unit. This five-year initiative will integrate Torays drug discovery and medical technology with the university expertise, infrastructure, and network to address the challenges of an aging society by improving the quality of life for the elderly and patients with progressive diseases.

Key Market Players

• Siemens Healthineers AG
• Myriad Genetics, Inc.
• Pfizer, Inc
• Novartis AG
• AstraZeneca plc
• Immunovia AB
• Laboratory Corporation of America Holdings
• Abbott Laboratories
• Agilent Technologies, Inc.
• Thermo Fisher Scientific Inc.

Report Scope:

In this report, the Global Pancreatic Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Pancreatic Cancer Diagnostics Market, By Test Type:

o   Diagnostic Imaging Tests

o   Biopsy

o   Blood Tests

o   Liver Function Tests

o   Others

• Pancreatic Cancer Diagnostics Market, By Cancer Type:

o   Exocrine

o   Adenocarcinoma

o   Squamous Cell Carcinoma

o   Colloid Carcinoma

o   Others

• Pancreatic Cancer Diagnostics Market, By End User:

o   Hospitals & Clinics

o   Diagnostic Centers

o   Others

• Pancreatic Cancer Diagnostics Market, By Region:

o   North America

§  United States

§  Mexico

§  Canada

o   Europe

§  France

§  Germany

§  United Kingdom

§  Italy

§  Spain

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Japan

§  Australia

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East and Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Pancreatic Cancer Diagnostics Market.

Available Customizations:

Global Pancreatic Cancer Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Pancreatic Cancer Diagnostics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]